Unfortunately, an evaluation of the IDH2 gene mutation status of the entire MPN-lymphoma cohort was not possible because of unavailability (or poor quality) of the tissue specimens that were acquired for sequencing. This evidence concerns the gene IDH2 and myeloproliferative disorder.